GENE vs. NKGN, PRPH, ME, IBIO, FLGC, SYBX, MRKR, NXTC, AYTU, and CLDI
Should you be buying Genetic Technologies stock or one of its competitors? The main competitors of Genetic Technologies include NKGen Biotech (NKGN), ProPhase Labs (PRPH), 23andMe (ME), iBio (IBIO), Flora Growth (FLGC), Synlogic (SYBX), Marker Therapeutics (MRKR), NextCure (NXTC), Aytu BioPharma (AYTU), and Calidi Biotherapeutics (CLDI). These companies are all part of the "pharmaceutical products" industry.
Genetic Technologies vs.
Genetic Technologies (NASDAQ:GENE) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings, profitability and community ranking.
Genetic Technologies received 161 more outperform votes than NKGen Biotech when rated by MarketBeat users.
0.6% of Genetic Technologies shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 6.5% of Genetic Technologies shares are held by company insiders. Comparatively, 10.4% of NKGen Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Genetic Technologies has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500.
In the previous week, Genetic Technologies had 9 more articles in the media than NKGen Biotech. MarketBeat recorded 10 mentions for Genetic Technologies and 1 mentions for NKGen Biotech. NKGen Biotech's average media sentiment score of 1.05 beat Genetic Technologies' score of 0.07 indicating that NKGen Biotech is being referred to more favorably in the news media.
Genetic Technologies has higher revenue and earnings than NKGen Biotech.
Summary
Genetic Technologies beats NKGen Biotech on 6 of the 10 factors compared between the two stocks.
Get Genetic Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for GENE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genetic Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:GENE) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy GENE Stock Free GENE Stock Alerts